3053716-98-3
Chemical Structure
YJ1206
- CAS No.: 3053716-98-3
- Formula:C49H52FN11O5
- Molecular Weight:894.01
InChIKey: SEWFPOHTHJEBQK-LINYYPFMSA-N
SMILES: O=C(NCC1=CC=CC=C1)N(C2=CN=C(N3CCN(C4CCN(C5=C(F)C=C(C(N(C6CCC(NC6=O)=O)C7=O)=O)C7=C5)CC4)CC3)C=C2)[C@H](CC8)CC[C@@H]8NC9=NC=C%10C(C=CC=C%10)=N9
Biological Activity: YJ1206 is an orally active selective CDK12/CDK13 PROTAC degrader. YJ1206 induces DNA damage and genomic instability, activates the AKT pathway, and triggers apoptosis. YJ1206 reduces tumor cell viability, inhibits tumor growth, and attenuates tumor cell dissemination. YJ1206 is applicable to research related to prostate cancer and high-grade serous tubo-ovarian cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
YJ1206 | 97.26% | YJ1206 is an orally active selective CDK12/CDK13 PROTAC degrader. YJ1206 induces DNA damage and genomic instability, activates the AKT pathway, and triggers apoptosis. YJ1206 reduces tumor cell viability, inhibits tumor growth, and attenuates tumor cell dissemination. YJ1206 is applicable to research related to prostate cancer and high-grade serous tubo-ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.80
HY-168162ZLC491 -
Similarity Score 0.65
HY-151110PROTAC CDK12/13 Degrader-1 -
Similarity Score 0.59
HY-168518PROTAC CDK9 degrader-9 -
Similarity Score 0.57
HY-160221PROTAC AR Degrader-7 -
Similarity Score 0.57
HY-155072PROTAC BTK Degrader-5 -
Similarity Score 0.56
HY-173066NU227326 -
Similarity Score 0.56
HY-168215YDR1 -
Similarity Score 0.55
HY-153821PROTAC KRAS G12C degrader-2 -
Similarity Score 0.55
HY-139436ARD-2585 -
Explore the MedChemAI to find more analogs
References
- [1]. Chang Y, et al. Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition. Cell Rep Med. 2024;5(10):101752. [Content Brief]
- [2]. Tien JC, et al. Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. Proc Natl Acad Sci U S A. 2025;122(24):e2426909122. [Content Brief]
